JP Morgan's survey of endocrinologists finds strong awareness of Crinetics' atumelnant, with positive efficacy impressions.

Lorundrostat demonstrated strong efficacy and safety in the pivotal Phase 3 Launch-HTN and Phase 2 Advance-HTN trials. These ...

Topline data were announced from a phase 3 trial investigating lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension.

RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced that its Phase 2 Advance-HTN trial data will be ...

We recently compiled a list of the 10 Pump and Dump Stocks Favored by Hedge Funds. In this article, we are going to take a ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities acted as joint book-running managers for the offering. LifeSci Capital acted as lead manager and H.C.

Researchers have discovered that a common form of high blood pressure is caused by tiny, non-cancerous growths in the adrenal ...

Two pivotal trials of the aldosterone synthase inhibitor have shown positive results for lorundrostat in uncontrolled and ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.

Mineralys Therapeutics said on Monday its experimental drug met the main goal of lowering blood pressure in patients with uncontrolled or resistant hypertension in late- and mid- stage trials, sending ...